 Holly Lindsay
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 18 | 2026 | 1318 | 2.840 |
Why?
| | Medulloblastoma | 7 | 2024 | 215 | 2.080 |
Why?
| | Central Nervous System Neoplasms | 7 | 2025 | 173 | 1.660 |
Why?
| | Cerebellar Neoplasms | 6 | 2024 | 177 | 1.610 |
Why?
| | Ependymoma | 5 | 2026 | 176 | 1.380 |
Why?
| | Glioma | 9 | 2025 | 425 | 1.320 |
Why?
| | Neoplastic Syndromes, Hereditary | 2 | 2019 | 45 | 1.180 |
Why?
| | Glioblastoma | 4 | 2026 | 353 | 1.100 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2026 | 23 | 0.950 |
Why?
| | Lymphopenia | 1 | 2024 | 65 | 0.820 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2026 | 1137 | 0.810 |
Why?
| | Hemophilia A | 2 | 2014 | 147 | 0.710 |
Why?
| | Neurocutaneous Syndromes | 1 | 2019 | 3 | 0.610 |
Why?
| | DNA Polymerase II | 1 | 2019 | 35 | 0.610 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 36 | 0.610 |
Why?
| | Child | 32 | 2026 | 22633 | 0.540 |
Why?
| | Cephalosporins | 1 | 2017 | 47 | 0.510 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2026 | 928 | 0.500 |
Why?
| | Factor VIII | 2 | 2014 | 104 | 0.500 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 251 | 0.500 |
Why?
| | Germinoma | 1 | 2016 | 10 | 0.480 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 72 | 0.460 |
Why?
| | Renal Insufficiency | 1 | 2017 | 168 | 0.440 |
Why?
| | Antineoplastic Agents | 6 | 2025 | 2194 | 0.430 |
Why?
| | Granuloma, Pyogenic | 1 | 2014 | 10 | 0.430 |
Why?
| | Coagulants | 1 | 2014 | 20 | 0.420 |
Why?
| | von Willebrand Disease, Type 2 | 1 | 2014 | 1 | 0.420 |
Why?
| | Infratentorial Neoplasms | 2 | 2026 | 71 | 0.420 |
Why?
| | Mouth Diseases | 1 | 2014 | 46 | 0.410 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 29 | 0.390 |
Why?
| | Child, Preschool | 15 | 2026 | 11787 | 0.390 |
Why?
| | Prognosis | 10 | 2026 | 4282 | 0.380 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 58 | 0.370 |
Why?
| | Adenosine Triphosphatases | 1 | 2013 | 162 | 0.360 |
Why?
| | Gene Deletion | 1 | 2013 | 389 | 0.350 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 845 | 0.340 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 259 | 0.330 |
Why?
| | DNA-Binding Proteins | 2 | 2019 | 1499 | 0.320 |
Why?
| | Chemoradiotherapy | 3 | 2026 | 237 | 0.300 |
Why?
| | Follow-Up Studies | 8 | 2026 | 5408 | 0.290 |
Why?
| | Humans | 39 | 2026 | 144759 | 0.280 |
Why?
| | Neoplasms | 4 | 2026 | 2875 | 0.270 |
Why?
| | Cancer Survivors | 2 | 2026 | 327 | 0.270 |
Why?
| | Neoplastic Stem Cells | 3 | 2024 | 412 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2026 | 1953 | 0.260 |
Why?
| | Adolescent | 15 | 2026 | 22428 | 0.260 |
Why?
| | Survival Rate | 4 | 2026 | 2089 | 0.250 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1907 | 0.240 |
Why?
| | Cell Line, Tumor | 6 | 2026 | 3540 | 0.240 |
Why?
| | Adenocarcinoma | 1 | 2013 | 928 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 118 | 0.230 |
Why?
| | Male | 20 | 2026 | 72315 | 0.230 |
Why?
| | Hydroxamic Acids | 1 | 2025 | 94 | 0.230 |
Why?
| | Pyrimidines | 4 | 2025 | 532 | 0.230 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2026 | 161 | 0.220 |
Why?
| | Mice, SCID | 4 | 2021 | 369 | 0.220 |
Why?
| | Cisplatin | 2 | 2024 | 334 | 0.220 |
Why?
| | Receptor, trkA | 1 | 2025 | 15 | 0.220 |
Why?
| | Gene Fusion | 1 | 2025 | 29 | 0.220 |
Why?
| | Female | 21 | 2026 | 78271 | 0.220 |
Why?
| | Proton Therapy | 1 | 2024 | 15 | 0.220 |
Why?
| | AC133 Antigen | 1 | 2024 | 20 | 0.210 |
Why?
| | CD57 Antigens | 1 | 2024 | 18 | 0.210 |
Why?
| | Craniospinal Irradiation | 1 | 2024 | 5 | 0.210 |
Why?
| | Gangliosides | 1 | 2024 | 23 | 0.210 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2025 | 220 | 0.210 |
Why?
| | Aftercare | 1 | 2026 | 223 | 0.210 |
Why?
| | MicroRNAs | 2 | 2021 | 701 | 0.210 |
Why?
| | Cochlea | 1 | 2024 | 73 | 0.200 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2024 | 105 | 0.200 |
Why?
| | Infant | 9 | 2026 | 10034 | 0.190 |
Why?
| | Methotrexate | 1 | 2024 | 240 | 0.190 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 210 | 0.190 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1313 | 0.190 |
Why?
| | Cell Survival | 1 | 2026 | 1098 | 0.190 |
Why?
| | Neoplasm Invasiveness | 1 | 2024 | 508 | 0.190 |
Why?
| | Young Adult | 9 | 2026 | 14105 | 0.180 |
Why?
| | Symporters | 1 | 2022 | 48 | 0.180 |
Why?
| | Aurora Kinase A | 2 | 2023 | 62 | 0.180 |
Why?
| | Craniopharyngioma | 1 | 2023 | 77 | 0.180 |
Why?
| | Spinal Cord Neoplasms | 1 | 2022 | 41 | 0.180 |
Why?
| | Azepines | 2 | 2023 | 107 | 0.180 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 56 | 0.170 |
Why?
| | Rhabdoid Tumor | 1 | 2023 | 103 | 0.170 |
Why?
| | Gadolinium | 1 | 2021 | 84 | 0.170 |
Why?
| | Pituitary Neoplasms | 1 | 2023 | 190 | 0.170 |
Why?
| | Hearing Loss | 1 | 2024 | 247 | 0.160 |
Why?
| | Phenotype | 3 | 2021 | 3162 | 0.160 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2020 | 72 | 0.160 |
Why?
| | Hypothalamic Diseases | 1 | 2020 | 17 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2020 | 73 | 0.160 |
Why?
| | Mice | 8 | 2026 | 18339 | 0.160 |
Why?
| | Methylphenidate | 1 | 2020 | 49 | 0.150 |
Why?
| | Neurofibromin 1 | 1 | 2019 | 26 | 0.150 |
Why?
| | Survival Analysis | 3 | 2020 | 1382 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 969 | 0.150 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2019 | 11 | 0.150 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2019 | 26 | 0.150 |
Why?
| | DNA Mismatch Repair | 1 | 2019 | 52 | 0.150 |
Why?
| | Animals | 11 | 2026 | 38058 | 0.150 |
Why?
| | Germ Cells | 1 | 2019 | 66 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.140 |
Why?
| | Histones | 2 | 2022 | 669 | 0.140 |
Why?
| | Digoxin | 1 | 2018 | 27 | 0.140 |
Why?
| | Multigene Family | 1 | 2019 | 204 | 0.140 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 172 | 0.140 |
Why?
| | Drug Repositioning | 1 | 2018 | 41 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 406 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 257 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2025 | 17066 | 0.140 |
Why?
| | Central Nervous System Stimulants | 1 | 2020 | 185 | 0.140 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 75 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2021 | 824 | 0.140 |
Why?
| | Systems Biology | 1 | 2018 | 72 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 375 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2021 | 688 | 0.130 |
Why?
| | Fever of Unknown Origin | 1 | 2017 | 13 | 0.130 |
Why?
| | Mutation | 4 | 2022 | 4089 | 0.130 |
Why?
| | Quality Improvement | 1 | 2026 | 1289 | 0.130 |
Why?
| | Caregivers | 1 | 2026 | 1049 | 0.120 |
Why?
| | Adult | 7 | 2026 | 40449 | 0.120 |
Why?
| | Genetic Testing | 1 | 2019 | 478 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 293 | 0.120 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 89 | 0.120 |
Why?
| | Quality of Life | 3 | 2023 | 3185 | 0.120 |
Why?
| | Radiation Tolerance | 1 | 2016 | 103 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2016 | 196 | 0.120 |
Why?
| | Heterografts | 1 | 2016 | 143 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 529 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1716 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2023 | 3863 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 462 | 0.110 |
Why?
| | Weight Loss | 1 | 2020 | 836 | 0.100 |
Why?
| | Chromosome Aberrations | 1 | 2014 | 162 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2363 | 0.100 |
Why?
| | von Willebrand Factor | 1 | 2014 | 85 | 0.100 |
Why?
| | Pediatrics | 1 | 2022 | 1114 | 0.100 |
Why?
| | Mismatch Repair Endonuclease PMS2 | 1 | 2013 | 4 | 0.100 |
Why?
| | Morpholines | 2 | 2025 | 128 | 0.100 |
Why?
| | Heterozygote | 1 | 2014 | 315 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2025 | 11679 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2026 | 1266 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2024 | 307 | 0.080 |
Why?
| | Alleles | 1 | 2013 | 879 | 0.080 |
Why?
| | Risk Factors | 1 | 2024 | 10779 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 610 | 0.070 |
Why?
| | Brain | 2 | 2021 | 2933 | 0.070 |
Why?
| | Recurrence | 2 | 2022 | 1135 | 0.070 |
Why?
| | Cell Proliferation | 3 | 2021 | 2496 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 919 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3077 | 0.060 |
Why?
| | Injections, Spinal | 1 | 2026 | 120 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2022 | 684 | 0.060 |
Why?
| | Sulfur Compounds | 1 | 2025 | 8 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2025 | 212 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4557 | 0.050 |
Why?
| | Apoptosis | 3 | 2018 | 2430 | 0.050 |
Why?
| | Cell Cycle | 2 | 2019 | 596 | 0.050 |
Why?
| | Receptor, trkB | 1 | 2025 | 36 | 0.050 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 11 | 0.050 |
Why?
| | Mucositis | 1 | 2024 | 20 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 108 | 0.050 |
Why?
| | Neutropenia | 1 | 2024 | 155 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 235 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2014 | 6429 | 0.050 |
Why?
| | Biphenyl Compounds | 1 | 2021 | 68 | 0.040 |
Why?
| | Dissection | 1 | 2021 | 56 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2021 | 289 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 194 | 0.040 |
Why?
| | Pyrazoles | 1 | 2025 | 509 | 0.040 |
Why?
| | Serial Passage | 1 | 2020 | 2 | 0.040 |
Why?
| | Government Regulation | 1 | 2020 | 38 | 0.040 |
Why?
| | Benzamides | 1 | 2021 | 224 | 0.040 |
Why?
| | Drug Interactions | 1 | 2022 | 398 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 337 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 45 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 881 | 0.040 |
Why?
| | Pyridones | 1 | 2021 | 199 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 203 | 0.040 |
Why?
| | Thalamus | 1 | 2021 | 125 | 0.040 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2019 | 28 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 76 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 64 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 332 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 119 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 85 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2019 | 183 | 0.030 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 102 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 2018 | 87 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2019 | 174 | 0.030 |
Why?
| | Contrast Media | 1 | 2021 | 488 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2019 | 192 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 372 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 681 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 339 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3333 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 318 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 322 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2018 | 155 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2014 | 33 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 2014 | 62 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1782 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1053 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 193 | 0.030 |
Why?
| | Genomics | 1 | 2019 | 834 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1173 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1455 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 1000 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 984 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1821 | 0.020 |
Why?
| | Aged | 2 | 2025 | 25913 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2608 | 0.020 |
Why?
| | Middle Aged | 2 | 2025 | 35875 | 0.020 |
Why?
| | Biomarkers | 1 | 2018 | 4271 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 5226 | 0.010 |
Why?
| | United States | 1 | 2020 | 15966 | 0.010 |
Why?
|
|
Lindsay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|